Operating Lease, Right-of-Use Asset of CRISPR Therapeutics AG from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
CRISPR Therapeutics AG quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • CRISPR Therapeutics AG Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $134,659,000, a 7.9% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

CRISPR Therapeutics AG Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $134,659,000 -$11,627,000 -7.9% 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $137,641,000 -$10,897,000 -7.3% 30 Jun 2025 10-Q 04 Aug 2025 2025 Q2
Q1 2025 $140,277,000 -$10,977,000 -7.3% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $143,461,000 -$10,532,000 -6.8% 31 Dec 2024 10-Q 10 Nov 2025 2025 Q3
Q3 2024 $146,286,000 -$9,929,000 -6.4% 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $148,538,000 -$10,814,000 -6.8% 30 Jun 2024 10-Q 05 Aug 2024 2024 Q2
Q1 2024 $151,254,000 -$2,092,000 -1.4% 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $153,993,000 -$2,928,000 -1.9% 31 Dec 2023 10-K 11 Feb 2025 2024 FY
Q3 2023 $156,215,000 -$5,292,000 -3.3% 30 Sep 2023 10-Q 06 Nov 2023 2023 Q3
Q2 2023 $159,352,000 -$7,388,000 -4.4% 30 Jun 2023 10-Q 07 Aug 2023 2023 Q2
Q1 2023 $153,346,000 -$18,195,000 -11% 31 Mar 2023 10-Q 08 May 2023 2023 Q1
Q4 2022 $156,921,000 -$17,539,000 -10% 31 Dec 2022 10-K 21 Feb 2024 2023 FY
Q3 2022 $161,507,000 -$13,625,000 -7.8% 30 Sep 2022 10-Q 01 Nov 2022 2022 Q3
Q2 2022 $166,740,000 -$12,641,000 -7% 30 Jun 2022 10-Q 08 Aug 2022 2022 Q2
Q1 2022 $171,541,000 +$121,412,000 +242% 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 $174,460,000 +$123,595,000 +243% 31 Dec 2021 10-K 21 Feb 2023 2022 FY
Q3 2021 $175,132,000 +$136,678,000 +355% 30 Sep 2021 10-Q 03 Nov 2021 2021 Q3
Q2 2021 $179,381,000 +$140,084,000 +356% 30 Jun 2021 10-Q 29 Jul 2021 2021 Q2
Q1 2021 $50,129,000 +$9,808,000 +24% 31 Mar 2021 10-Q 27 Apr 2021 2021 Q1
Q4 2020 $50,865,000 +$9,363,000 +23% 31 Dec 2020 10-K 15 Feb 2022 2021 FY
Q3 2020 $38,454,000 +$7,835,000 +26% 30 Sep 2020 10-Q 28 Oct 2020 2020 Q3
Q2 2020 $39,297,000 +$8,527,000 +28% 30 Jun 2020 10-Q 27 Jul 2020 2020 Q2
Q1 2020 $40,321,000 +$15,223,000 +61% 31 Mar 2020 10-Q 28 Apr 2020 2020 Q1
Q4 2019 $41,502,000 31 Dec 2019 10-K 16 Feb 2021 2020 FY
Q3 2019 $30,619,000 30 Sep 2019 10-Q 28 Oct 2019 2019 Q3
Q2 2019 $30,770,000 30 Jun 2019 10-Q 29 Jul 2019 2019 Q2
Q1 2019 $25,098,000 31 Mar 2019 10-Q 29 Apr 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.